Physician profile
Catherine Bussieres
NPI 1619984457
$4,837.68
in general payments reported to CMS, 2019-2025
30 companies · $895 in 2025
The $895 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $406 · 2021: $471 · 2022: $881 · 2023: $1,142 · 2024: $813 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,190.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $581.29 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $508.66 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $482.39 | 2019-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $328.14 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $278.36 | 2019-2025 | Capvaxive, Belsomra, Steglatro |
| Pfizer INC. | $229.99 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $211.93 | 2020-2025 | Livalo, Seglentis, Zoryve |
| Abbvie INC. | $141.31 | 2023-2024 | Ubrelvy, Qulipta |
| Horizon Therapeutics Plc | $118.68 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.91 | 2022-2025 | |
| Amarin Pharma, INC. | $92.32 | 2019-2020 | |
| Esperion Therapeutics, INC. | $83.53 | 2021 | |
| Sanofi Pasteur INC. | $80.29 | 2019-2025 | |
| Exact Sciences Corporation | $72.36 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.48 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $32.03 | 2020 | |
| Radius Health, INC. | $31.55 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2019-2023 | Trulance, Xifaxan |
| Ibsa Pharma INC. | $28.62 | 2022 | |
| Phadia US INC. | $22.22 | 2024 | Immunocap |
| Genentech USA, INC. | $20.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.70 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.92 | 2023 | |
| Currax Pharmaceuticals LLC | $17.01 | 2023 | Contrave |
| Tolmar, INC. | $16.78 | 2025 | Jatenzo |
| Shield Therapeutics INC | $15.14 | 2024 | |
| Seqirus USA INC | $11.72 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.69 | 2022 | |
| Vistapharm, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Bussieres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.